Product Information
Registration Status: ActiveSIN11413P
UPLORES CAPSULE 150mg is approved to be sold in Singapore with effective from 2000-10-20. It is marketed by EURO ASIA MEDICO PTE LTD, with the registration number of SIN11413P.
This product contains Roxithromycin 150mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by PT SANBE FARMA in INDONESIA REP OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Roxithromycin is a semi-synthetic macrolide antibiotic. It is very similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, or clarithromycin. Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. It can treat respiratory tract, urinary and soft tissue infections. It is not available in the United States, but is available in Australia.
Indication
Used to treat respiratory tract, urinary and soft tissue infections.
Mechanism of Action
Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila.
Pharmacokinetics
- Absorption
- Very rapidly absorbed and diffused into most tissues and phagocytes.
- Distribution
- Metabolism
- Hepatic. Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged. Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites. The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces.
- Elimination
Toxicity
Most common side-effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.
Active Ingredient/Synonyms
(9e)-Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime) | Roxithromycin | Roxithromycine | Roxithromycinum | Roxitromicina | Roxithromycin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.